Moderna Inc [NASDAQ: MRNA] surged by $11.85 during the normal trading session on while it closed the day at $99.44. The company report on February 22, 2024 at 6:30 AM that Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates.
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55.
Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowance.
Moderna Inc stock has also gained 15.70% of its value over the past 7 days. However, MRNA stock has inclined by 25.94% in the 3 months of the year. Over the past six months meanwhile, it has lost -14.45% and lost -0.01% year-on date.
The market cap for MRNA stock reached $37.91 billion, with 385.00 million shares outstanding and 334.69 million shares in the current float. Compared to the average trading volume of 4.76M shares, MRNA reached a trading volume of 11313494 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Moderna Inc [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $128.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.32. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Moderna Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 02, 2024. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Hold. The new note on the price target was released on November 29, 2023, representing the official price target for Moderna Inc stock. Previously, the target price had yet another drop from $89 to $69, while HSBC Securities kept a Hold rating on MRNA stock. On November 02, 2023, analysts decreased their price target for MRNA shares from 125 to 60.
The Average True Range (ATR) for Moderna Inc is set at 5.04, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 4.18. The Price to Book ratio for the last quarter was 2.82, with the Price to Cash per share for the same quarter was set at 19.86.
MRNA stock trade performance evaluation
Moderna Inc [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.70. With this latest performance, MRNA shares dropped by -2.43% in over the last four-week period, additionally sinking by -14.45% over the last 6 months – not to mention a drop of -37.88% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 56.11, with the RSI for the last a single of trading hit 61.18, and the three-weeks RSI is set at 54.28 for Moderna Inc [MRNA]. The present Moving Average for the last 50 days of trading for this stock 96.91, while it was recorded at 90.71 for the last single week of trading, and 103.64 for the last 200 days.
Moderna Inc [MRNA]: An insightful look at the core fundamentals
Moderna Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.35 and a Current Ratio set at 2.46.
Earnings per share (EPS) analysis for Moderna Inc [MRNA] stock
With the latest financial reports released by the company, Moderna Inc posted 3.61/share EPS, while the average EPS was predicted by analysts to be reported at 4.68/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -22.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA.
Moderna Inc [MRNA]: Institutional Ownership
The top three institutional holders of MRNA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in MRNA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in MRNA stock with ownership which is approximately 5.8325%.
